Autolus Therapeutics plc (AUTL) NASDAQ

1.51

+0.035(+2.38%)

Updated at May 22 10:03AM

Currency In USD

Autolus Therapeutics plc

Address

The MediaWorks

London, W12 7FP

United Kingdom of Great Britain and Northern Ireland

Phone

44 20 3829 6230

Sector

Healthcare

Industry

Biotechnology

Employees

647

First IPO Date

June 22, 2018

Key Executives

NameTitlePayYear Born
Dr. Christian Martin Itin Ph.D.Chief Executive Officer & Director2.57M1964
Mr. Alexander SwanSenior Vice President & Chief Human Resources Officer01965
Dr. Christopher WilliamsChief Business Officer01980
Dr. Martin Pule M.D., MBBSFounder, Senior Vice President & Chief Scientific Officer01972
Dr. Matthias Will M.D.Senior Vice President & Chief Development Officer01973
Ms. Olivia ManserDirector of Investor Relations0N/A
Mr. Christopher VannSenior Vice President & Chief Operating Officer01965
Mr. Alex DriggsSenior Vice President of Legal Affairs & General Counsel and Secretary01976
Mr. Robert F. DolskiSenior Vice President, Chief Financial Officer & Principal Accounting Officer01970
Mr. David BrochuSenior Vice President & Chief Technical Officer01956

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.